Fig. 1
From: microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1
The levels of miR-21 in breast cancer patient plasma and cell lines. a Plasma miR-21 levels in 252 breast cancer patients, 127 healthy controls, and 82 benign breast cancer patients (p < 0.0001). b Plasma miR-21 levels of 44 paired plasma samples from breast cancer patients before and after surgery (p < 0.05). c Plasma miR-21 levels in the lymph nodes of metastasis-negative (LN0) or -positive (LNx) breast cancer patients (p < 0.01). d Plasma miR-21 levels in benign breast cancer and stage T1, T2, and T3 breast cancer patients (p < 0.01). e Plasma miR-21 levels in luminal A, luminal B, Her-2+ and basal-like types of breast cancer patients (p < 0.05). f The mRNA levels of miR-21 in HBL-100, Hs578T, MDA-MB-231, SK-BR3, and MCF-7 cell lines (*p < 0.05, **p < 0.01, ***p < 0.001)